Partnership Integrated Genomic and Epigenomic Analysis
A new collaboration automates diagnostic workflows to help laboratories identify rare conditions more efficiently.
Updated on Oct. 5, 2026 in Diseases — General
Live Poll
Do you believe partnerships between diagnostic firms improve the quality of patient care?
EpiSign and Geneyx have launched a partnership that integrates DNA methylation episignature analysis with comprehensive genomic and multi-omics capabilities. This integration aims to streamline the diagnostic process for patients by consolidating complex testing workflows.
Why it matters
By combining genomic and epigenomic evidence into a single assay, this collaboration seeks to resolve rare-disease cases faster while reducing overall laboratory testing costs. The initiative focuses on shortening diagnostic timelines, which are often significant hurdles for patients with complex health conditions.
The integrated system supports analysis for over 300 conditions using Illumina 5-base, PacBioHiFi, and Oxford Nanopore sequencing data. This analysis is currently categorized for research use only.
The players
EpiSign
A developer of DNA methylation episignature analysis tools used to identify rare genetic and epigenetic conditions.
Geneyx
A genomic software company that provides analytical platforms for complex clinical and research sequencing data.
The details
The collaboration enables laboratories to process genomic and epigenomic information through a single automated workflow via the EpiSign METRIC software. This approach minimizes the need for sequential testing, allowing clinicians to review phenotypic, genomic, and methylation data simultaneously. By leveraging this unified system, laboratories can detect molecular patterns associated with rare diseases that might otherwise remain unidentified through standard sequencing alone.
Timeline
October 5, 2026: EpiSign and Geneyx announced their formal partnership.
Health Landscape
The integration of multi-omics capabilities reflects a broader trend toward more unified diagnostic testing in molecular medicine. This approach represents a shift from traditional, step-wise genetic testing toward high-throughput, integrated platforms designed to resolve diagnostic odysseys.
For patients navigating a diagnostic search for rare conditions, this development may eventually lead to faster access to precise genetic answers. It is worth discussing with your physician or genetic counselor whether updated multi-omics testing options might be appropriate for your specific case.
The takeaway
Integrated molecular testing is improving how laboratories identify the genetic drivers of rare diseases. Patients or families seeking diagnostic clarity should ask their clinical care team if specialized epigenetic analysis is available to complement their existing genetic sequencing results.
Further reading
Learn more about the latest innovations in diagnostic testing within our Diseases — General section.
Live Poll
Do you believe partnerships between diagnostic firms improve the quality of patient care?
